- Home
- FOIL vs SYRE Comparison
FOIL vs SYRE Comparison
Compare FOIL & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FOIL
Londian Wason New Energy Tech Inc. American Depositary Shares each representing five Ordinary Shares
Current Price
Current Price
Company Overview
Basic Information| Metric | FOIL | SYRE |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6B | 7.6B |
| IPO Year | 2024 | 2015 |
Fundamental Metrics
Financial Performance| Metric | FOIL | SYRE |
|---|---|---|
| Price | $16.25 | $89.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $120.08 |
| AVG Volume (30 Days) | 25.5K | ★ 950.4K |
| Earning Date | 10-06-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $69.43 | N/A |
| Revenue Next Year | $10.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.89 | $15.88 |
| 52 Week High | $25.44 | $110.18 |
Technical Indicators
Market Signals| Indicator | FOIL | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 27.01 | 50.99 |
| Support Level | N/A | $82.86 |
| Resistance Level | $21.40 | $93.65 |
| Average True Range (ATR) | 1.73 | 3.49 |
| MACD | -0.31 | 0.31 |
| Stochastic Oscillator | 2.89 | 70.47 |
Price Performance
Historical ComparisonAbout FOIL Londian Wason New Energy Tech Inc. American Depositary Shares each representing five Ordinary Shares
Londian Wason New Energy Tech Inc is engaged in the research, development, and manufacture of electrolytic copper foil. Its product portfolio includes lithium-ion battery (LiB) copper foil, printed circuit board (PCB)-grade copper foil, and flexible copper clad laminates (FCCLs). Its products are used in applications including electric vehicles, energy storage systems, communication equipment, and consumer electronics. The company derives its revenue from contracts with customers, including the sales of LiB copper foil, PCB-grade copper foil and others in the PRC.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.